News & Literature Highlights
March 2021
-
Novel Immunotherapies
Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated With Cytokine Release Syndrome Induced by CAR T-Cell Therapy
Clinical Cancer Research
-
Kinase Inhibitors
Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
2020 ASH Annual Meeting
-
HER2-Targeted Therapies
Deceleration Capacity of Heart Rate Predicts Trastuzumab‐Related Cardiotoxicity in Patients With HER2‐Positive Breast Cancer: A Prospective Observational Study
Journal of Clinical Pharmacy and Therapeutics
-
HER2-Targeted Therapies
Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
Frontiers in Pharmacology
-
HER2-Targeted Therapies
Mechanisms and Potential Interventions Associated With the Cardiotoxicity of ErbB2-Targeted Drugs: Insights From in vitro, in vivo, and Clinical Studies in Breast Cancer Patients
Cellular and Molecular Life Sciences
-
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries
Circulation
-
Immune Checkpoint Inhibitors
ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data From the ECoR Registry
Journal of Clinical Medicine
-
Immune Checkpoint Inhibitors
How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
Frontiers in Pharmacology
February 2021
-
Novel Immunotherapies
Impact of Cytokine Release Syndrome on Cardiac Function Following CD19 CAR-T Cell Therapy in Children and Young Adults With Hematological Malignancies
Journal for ImmunoTherapy of Cancer
-
Kinase Inhibitors
Transcriptomic Profiling of Human Cardiac Cells Predicts Protein Kinase Inhibitor-Associated Cardiotoxicity
Nature Communications
-
HER2-Targeted Therapies
The Role of Cardio-Protective Agents in Cardio-Preservation in Breast Cancer Patients Receiving Anthracyclines ± Trastuzumab: A Meta-Analysis of Clinical Studies
Critical Reviews in Oncology/Hematology
-
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity
Immunotherapy
January 2021
-
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure
Annual Review of Pharmacology and Toxicology
-
Novel Immunotherapies
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective
Frontiers in Oncology
-
HER2-Targeted Therapies
Real‐World Impact of Anti‐HER2 Therapy‐Related Cardiotoxicity in Patients With Advanced HER2‐Positive Breast Cancer
Asia-Pacific Journal of Clinical Oncology
-
Kinase Inhibitors
Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
JACC: CardioOncology
December 2020
-
Novel Immunotherapies
Getting to the Heart of CAR T-Cell Therapy’s Cardiovascular Risks
Cell Therapy Next
-
Kinase Inhibitors
Osimertinib Induced Cardiomyopathy: A Case Report
Medicine
-
HER2-Targeted Therapies
Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population-Based Cohort Study
The Oncologist
-
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
Frontiers in Pharmacology
November 2020
-
Novel Immunotherapies
Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years
Journal of Geriatric Oncology
-
HER2-Targeted Therapies
Cardiotoxicity Manifestations in Metastatic Breast Cancer Patients Treated With Trastuzumab as First Line
2020 ASCO Virtual Scientific Program
-
Kinase Inhibitors
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
American Journal of Managed Care
-
Immune Checkpoint Inhibitors
Cardiotoxicity From Immune Checkpoint Inhibitors
IJC Heart and Vasculature
October 2020
-
Immune Checkpoint Inhibitors
Cardiotoxicity Associated With Immune Checkpoint Inhibitors: A Systemic Review and Meta-Analysis
ASCO Annual Meeting 2020 (Abstract)
-
HER2-Targeted Therapies
Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy
Frontiers in Oncology
-
Novel Immunotherapies
Cardiotoxic Mechanisms of Cancer Immunotherapy – A Systematic Review
International Journal of Cardiology
-
Kinase Inhibitors
Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Current Treatment Options in Oncology
September 2020
-
HER2-Targeted Therapies
Genotypes and Comorbidities Associated With Trastuzumab-Induced Cardiotoxicity in HER2+ Breast Cancer
Targeted Oncology
-
HER2-Targeted Therapies
Long-Term Follow-Up Assessment of Cardiac Safety in SAFE-HEaRt, a Clinical Trial Evaluating the Use of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function
ASCO Annual Meeting 2020 (Abstract/Poster)
-
Kinase Inhibitors
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase II PACE Trial (NCT01207440) in Patients (pts) With Ph+ Leukemia
2020 ASCO Annual Meeting (Abstract/Poster)
-
Kinase Inhibitors
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
Frontiers in Pharmacology
-
Novel Immunotherapies
Patient Death Puts Trial on Hold for Universal CAR-T in Myeloma
Cancer Therapy Advisor
-
Novel Immunotherapies
New VTE Incidence ‘Significant’ After CAR T-Cell Therapy for Lymphoma
Healio: Hematology/Oncology
-
Immune Checkpoint Inhibitors
New Insights Into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity
Current Oncology Reports
-
Immune Checkpoint Inhibitors
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis
Circulation
-
General Cardio-Oncology
The Role of Biomarkers to Evaluate Cardiotoxicity
Current Treatment Options in Oncology
-
General Cardio-Oncology
Preventing Today’s Survivors of Breast Cancer From Becoming Tomorrow’s Cardiac Patients
JCO Oncology Practice
-
General Cardio-Oncology
Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World
Frontiers in Cardiovascular Medicine
August 2020
-
Novel Immunotherapies
The Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy
Current Hematologic Malignancy Reports
-
Novel Immunotherapies
Cardiovascular Risk Profile of Chimeric Antigen Receptor T-Cell Therapy
Cureus
-
Kinase Inhibitors
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience
Oncology
-
Kinase Inhibitors
Precision Cardio-Oncology: A Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
Journal of Cardiovascular Translational Research
-
HER2-Targeted Therapies
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2-Targeted Therapy
JACC: CardioOncology
-
HER2-Targeted Therapies
Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction
American Journal of Cardiology
-
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor–Related Adverse Cardiovascular Events in Patients With Lung Cancer
JACC: CardioOncology
-
Immune Checkpoint Inhibitors
Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
American Journal of Cardiology
July 2020
-
Novel Immunotherapies
Strategic Management of CAR T Cells in Hematologic Malignancies
Targeted Oncology
-
Novel Immunotherapies
Cardiovascular Effects of CAR T-Cell Therapy: A Retrospective Study
JACC: CardioOncology
-
Novel Immunotherapies
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Journal of the American College of Cardiology
-
HER2-Targeted Therapies
Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
JACC: CardioOncology
-
HER2-Targeted Therapies
Trastuzumab Emtansine (T-DM1)-Associated Cardiotoxicity: Pooled Analysis in Advanced HER2-Positive Breast Cancer
European Journal of Cancer
-
HER2-Targeted Therapies
Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer
American Journal of Cardiology
-
Kinase Inhibitors
Electrocardiographic Changes Associated With Ibrutinib Exposure
Cancer Control
-
Kinase Inhibitors
Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib
International Journal of Cardiology
-
Immune Checkpoint Inhibitors
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor–Related Myocarditis
American Journal of the College of Cardiology
-
Immune Checkpoint Inhibitors
Late Cardiac Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors
Journal for ImmunoTherapy of Cancer
June 2020
-
Immune Checkpoint Inhibitors
Clinical Manifestation and Management of Immune Checkpoint Inhibitor–Associated Cardiotoxicity
Thoracic Cancer
-
HER2-Targeted Therapies
HER2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management
Breast Cancer Research and Treatment
-
Kinase Inhibitors
Real-World Data Highlight Cardiac AEs With Osimertinib
Medscape
-
Kinase Inhibitors
Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
JACC: CardioOncology
-
Novel Immunotherapies
CAR T-Cell Therapy–Related Cardiovascular Outcomes and Management, Systemic Disease or Direct Cardiotoxicity?
JACC: CardioOncology
May 2020
-
HER2-Targeted Therapies
Long-Term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer
JAMA Cardiology
-
Novel Immunotherapies
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives
Journal of the American College of Cardiology
-
Kinase Inhibitors
Early Diagnosis, Clinical Management, and Follow-up of Cardiovascular Events with Ponatinib
Heart Failure Reviews
-
Immune Checkpoint Inhibitors
Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy are at an Increased Risk for Atherosclerotic Cardiovascular Disease
Journal for ImmunoTherapy of Cancer
-
General Cardio-Oncology
Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation
The ASCO Post
-
General Cardio-Oncology
Metabolic Changes May Signal Development of Chemotherapy-Associated Cardiotoxicity
The ASCO Post
-
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
Journal of the American Heart Association
